[Business Wire] – DALLAS–(BUSINESSWIRE)– New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two . . . → Read More: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Results from B-YOND Extension Study Reinforce Long-Term Clinical Profile of ALPROLIX for the Treatment of Hemophilia B Similar Articles: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen 2015 Annual Shareholder Meeting Webcast Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Inc. (Nasdaq: BIIB) to Ring The Nasdaq Stock Market Opening Bell Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair